A
Andrei Voznesensky
Researcher at Bayer Schering Pharma AG
Publications - 3
Citations - 3816
Andrei Voznesensky is an academic researcher from Bayer Schering Pharma AG. The author has contributed to research in topics: Receptor tyrosine kinase & Cancer. The author has an hindex of 3, co-authored 3 publications receiving 3597 citations.
Papers
More filters
Journal ArticleDOI
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
Scott Wilhelm,Christopher A. Carter,LiYa Tang,Dean Wilkie,Angela McNabola,Hong Rong,Charles Chen,Xiaomei Zhang,Patrick Vincent,Mark McHugh,Yichen Cao,Jaleel Shujath,Susan Gawlak,Deepa Eveleigh,Bruce Rowley,Li Liu,Lila Adnane,Mark Lynch,Daniel Auclair,Ian W. Taylor,Rich Gedrich,Andrei Voznesensky,Bernd Riedl,Leonard Post,Gideon Bollag,Pamela A. Trail +25 more
TL;DR: Data demonstrate that BAY 43-9006 is a novel dual action RAF kinase and VEGFR inhibitor that targets tumor cell proliferation and tumor angiogenesis.
Journal ArticleDOI
Therapeutic Mechanism and Efficacy of the Antibody–Drug Conjugate BAY 79-4620 Targeting Human Carbonic Anhydrase 9
Heike Petrul,Christoph Schatz,Charlotte Christine Kopitz,Lila Adnane,Timothy Mccabe,Pamela A. Trail,Sha Ha,Yong S. Chang,Andrei Voznesensky,Gerald Ranges,Paul Tamburini +10 more
TL;DR: In preclinical human xenograft models in mice representing several tumor indications, BAY 79-4620 showed potent antitumor efficacy and in some models showed partial and complete tumor shrinkage even following a single dose.
Proceedings ArticleDOI
Abstract 2577: In vitro and in vivo efficacy of the anti-MN immunoconjugate BAY 79-4620, MN-IC, in MN (CAIX) expressing preclinical tumor models
Heike Petrul,Gerald Ranges,Elizabeth Bouret,Yong Chang,Andrei Voznesensky,Christoph Schatz,Charlotte Kopitz,Paul Tamburini,Karl Ziegelbauer +8 more
TL;DR: It is demonstrated that targeted delivery of MMAE resulted in higher efficacy of BAY 79-4620 in tumor models with high CAIX expression, and treatment with the immunoconjugate was found to be less toxic than that with free MMAE.